Drug Trial Radar · NCT03125642
Auto Stem Cell Transplant for Lymphoma Patients
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Apr 20, 2017
Primary completion
Sep 30, 2027
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
Conditions
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
Interventions
EtoposideDrug
BEAM: 100 mg/m\^2 IV over 2 hours BID on Days -5, -4, -3, -2 \| CBV: 150 mg/m\^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4
BCNUDrug
BEAM \& CBV: 300 mg/m\^2 IV over over 2 hours on Day -6
AraCDrug
BEAM: 100 mg/m\^2 IV over 1 hour BID on Days -5, -4, -3, -2
MelphalanDrug
BEAM: 140 mg/m\^2 IV over 20 minutes on Day -1
Peripheral blood stem cell transplantationProcedure
All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.
G-CSFBiological
All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is \>2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3
CyclophosphamideDrug
CBV: 1.5 gm/M\^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 \| CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6
Total Body IrradiationRadiation
CY/TBI: 165 cGy bid on Day -4, -3, -2, -1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival ComparisonTime frame: 3 years post transplant
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.